Literature DB >> 29394990

Functional Dysregulation of CDC42 Causes Diverse Developmental Phenotypes.

Simone Martinelli1, Oliver H F Krumbach2, Francesca Pantaleoni3, Simona Coppola4, Ehsan Amin2, Luca Pannone3, Kazem Nouri2, Luciapia Farina4, Radovan Dvorsky2, Francesca Lepri3, Marcel Buchholzer2, Raphael Konopatzki2, Laurence Walsh5, Katelyn Payne5, Mary Ella Pierpont6, Samantha Schrier Vergano7, Katherine G Langley8, Douglas Larsen9, Kelly D Farwell10, Sha Tang10, Cameron Mroske10, Ivan Gallotta11, Elia Di Schiavi11, Matteo Della Monica12, Licia Lugli13, Cesare Rossi14, Marco Seri15, Guido Cocchi15, Lindsay Henderson8, Berivan Baskin8, Mariëlle Alders16, Roberto Mendoza-Londono17, Lucie Dupuis18, Deborah A Nickerson19, Jessica X Chong20, Naomi Meeks21, Kathleen Brown21, Tahnee Causey22, Megan T Cho8, Stephanie Demuth23, Maria Cristina Digilio3, Bruce D Gelb24, Michael J Bamshad25, Martin Zenker26, Mohammad Reza Ahmadian2, Raoul C Hennekam27, Marco Tartaglia28, Ghayda M Mirzaa29.   

Abstract

Exome sequencing has markedly enhanced the discovery of genes implicated in Mendelian disorders, particularly for individuals in whom a known clinical entity could not be assigned. This has led to the recognition that phenotypic heterogeneity resulting from allelic mutations occurs more commonly than previously appreciated. Here, we report that missense variants in CDC42, a gene encoding a small GTPase functioning as an intracellular signaling node, underlie a clinically heterogeneous group of phenotypes characterized by variable growth dysregulation, facial dysmorphism, and neurodevelopmental, immunological, and hematological anomalies, including a phenotype resembling Noonan syndrome, a developmental disorder caused by dysregulated RAS signaling. In silico, in vitro, and in vivo analyses demonstrate that mutations variably perturb CDC42 function by altering the switch between the active and inactive states of the GTPase and/or affecting CDC42 interaction with effectors, and differentially disturb cellular and developmental processes. These findings reveal the remarkably variable impact that dominantly acting CDC42 mutations have on cell function and development, creating challenges in syndrome definition, and exemplify the importance of functional profiling for syndrome recognition and delineation.
Copyright © 2017 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Noonan syndrome; cardiac defects; developmental anomalies; exome sequencing; functional profiling; genotype-phenotype correlations; microcephaly; mutation spectrum; phenotypic heterogeneity; thrombocytopenia

Mesh:

Substances:

Year:  2018        PMID: 29394990      PMCID: PMC5985417          DOI: 10.1016/j.ajhg.2017.12.015

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  54 in total

1.  Structure of Cdc42 bound to the GTPase binding domain of PAK.

Authors:  A Morreale; M Venkatesan; H R Mott; D Owen; D Nietlispach; P N Lowe; E D Laue
Journal:  Nat Struct Biol       Date:  2000-05

Review 2.  Cdc42--the centre of polarity.

Authors:  Sandrine Etienne-Manneville
Journal:  J Cell Sci       Date:  2004-03-15       Impact factor: 5.285

3.  Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies.

Authors:  Chengliang Dong; Peng Wei; Xueqiu Jian; Richard Gibbs; Eric Boerwinkle; Kai Wang; Xiaoming Liu
Journal:  Hum Mol Genet       Date:  2014-12-30       Impact factor: 6.150

4.  De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies.

Authors:  Jason Homsy; Samir Zaidi; Yufeng Shen; James S Ware; Kaitlin E Samocha; Konrad J Karczewski; Steven R DePalma; David McKean; Hiroko Wakimoto; Josh Gorham; Sheng Chih Jin; John Deanfield; Alessandro Giardini; George A Porter; Richard Kim; Kaya Bilguvar; Francesc López-Giráldez; Irina Tikhonova; Shrikant Mane; Angela Romano-Adesman; Hongjian Qi; Badri Vardarajan; Lijiang Ma; Mark Daly; Amy E Roberts; Mark W Russell; Seema Mital; Jane W Newburger; J William Gaynor; Roger E Breitbart; Ivan Iossifov; Michael Ronemus; Stephan J Sanders; Jonathan R Kaltman; Jonathan G Seidman; Martina Brueckner; Bruce D Gelb; Elizabeth Goldmuntz; Richard P Lifton; Christine E Seidman; Wendy K Chung
Journal:  Science       Date:  2015-12-04       Impact factor: 47.728

Review 5.  Targeting Cdc42 in cancer.

Authors:  Luis E Arias-Romero; Jonathan Chernoff
Journal:  Expert Opin Ther Targets       Date:  2013-08-19       Impact factor: 6.902

6.  An electrostatic steering mechanism of Cdc42 recognition by Wiskott-Aldrich syndrome proteins.

Authors:  Lars Hemsath; Radovan Dvorsky; Dennis Fiegen; Marie-France Carlier; Mohammad Reza Ahmadian
Journal:  Mol Cell       Date:  2005-10-28       Impact factor: 17.970

7.  GeneMatcher: a matching tool for connecting investigators with an interest in the same gene.

Authors:  Nara Sobreira; François Schiettecatte; David Valle; Ada Hamosh
Journal:  Hum Mutat       Date:  2015-08-13       Impact factor: 4.878

8.  The structure of FMNL2-Cdc42 yields insights into the mechanism of lamellipodia and filopodia formation.

Authors:  Sonja Kühn; Constanze Erdmann; Frieda Kage; Jennifer Block; Lisa Schwenkmezger; Anika Steffen; Klemens Rottner; Matthias Geyer
Journal:  Nat Commun       Date:  2015-05-12       Impact factor: 14.919

9.  Abl-dependent tyrosine phosphorylation of Sos-1 mediates growth-factor-induced Rac activation.

Authors:  Patrizia Sini; Angela Cannas; Anthony J Koleske; Pier Paolo Di Fiore; Giorgio Scita
Journal:  Nat Cell Biol       Date:  2004-02-22       Impact factor: 28.824

10.  Candidate-gene criteria for clinical reporting: diagnostic exome sequencing identifies altered candidate genes among 8% of patients with undiagnosed diseases.

Authors:  Kelly D Farwell Hagman; Deepali N Shinde; Cameron Mroske; Erica Smith; Kelly Radtke; Layla Shahmirzadi; Dima El-Khechen; Zöe Powis; Elizabeth C Chao; Wendy A Alcaraz; Katherine L Helbig; Samin A Sajan; Mari Rossi; Hsiao-Mei Lu; Robert Huether; Shuwei Li; Sitao Wu; Mark E Nuñes; Sha Tang
Journal:  Genet Med       Date:  2016-08-11       Impact factor: 8.822

View more
  44 in total

1.  Activating Mutations of RRAS2 Are a Rare Cause of Noonan Syndrome.

Authors:  Yline Capri; Elisabetta Flex; Oliver H F Krumbach; Giovanna Carpentieri; Serena Cecchetti; Christina Lißewski; Soheila Rezaei Adariani; Denny Schanze; Julia Brinkmann; Juliette Piard; Francesca Pantaleoni; Francesca R Lepri; Elaine Suk-Ying Goh; Karen Chong; Elliot Stieglitz; Julia Meyer; Alma Kuechler; Nuria C Bramswig; Stephanie Sacharow; Marion Strullu; Yoann Vial; Cédric Vignal; George Kensah; Goran Cuturilo; Neda S Kazemein Jasemi; Radovan Dvorsky; Kristin G Monaghan; Lisa M Vincent; Hélène Cavé; Alain Verloes; Mohammad R Ahmadian; Marco Tartaglia; Martin Zenker
Journal:  Am J Hum Genet       Date:  2019-05-23       Impact factor: 11.025

Review 2.  Molecular mechanisms of phenotypic variability in monogenic autoinflammatory diseases.

Authors:  Ivona Aksentijevich; Oskar Schnappauf
Journal:  Nat Rev Rheumatol       Date:  2021-05-25       Impact factor: 20.543

Review 3.  RHO GTPases: from new partners to complex immune syndromes.

Authors:  Rana El Masri; Jérôme Delon
Journal:  Nat Rev Immunol       Date:  2021-02-05       Impact factor: 53.106

Review 4.  Pediatric hemophagocytic lymphohistiocytosis.

Authors:  Scott W Canna; Rebecca A Marsh
Journal:  Blood       Date:  2020-04-16       Impact factor: 22.113

5.  Dominant activating RAC2 mutation with lymphopenia, immunodeficiency, and cytoskeletal defects.

Authors:  Amy P Hsu; Agnes Donkó; Megan E Arrington; Muthulekha Swamydas; Danielle Fink; Arundhoti Das; Omar Escobedo; Vincent Bonagura; Paul Szabolcs; Harry N Steinberg; Jenna Bergerson; Amanda Skoskiewicz; Melanie Makhija; Joie Davis; Ladan Foruraghi; Cindy Palmer; Ramsay L Fuleihan; Joseph A Church; Avinash Bhandoola; Michail S Lionakis; Sharon Campbell; Thomas L Leto; Douglas B Kuhns; Steven M Holland
Journal:  Blood       Date:  2019-02-05       Impact factor: 22.113

6.  Activating Mutations in PAK1, Encoding p21-Activated Kinase 1, Cause a Neurodevelopmental Disorder.

Authors:  Frederike L Harms; Katja Kloth; Annette Bley; Jonas Denecke; René Santer; Davor Lessel; Maja Hempel; Kerstin Kutsche
Journal:  Am J Hum Genet       Date:  2018-10-04       Impact factor: 11.025

7.  The Growing Spectrum of Human Diseases Caused by Inherited CDC42 Mutations.

Authors:  Helen C Su; Jordan S Orange
Journal:  J Clin Immunol       Date:  2020-05       Impact factor: 8.317

8.  Common genetic variants contribute to risk of rare severe neurodevelopmental disorders.

Authors:  Mari E K Niemi; Hilary C Martin; Daniel L Rice; Giuseppe Gallone; Scott Gordon; Martin Kelemen; Kerrie McAloney; Jeremy McRae; Elizabeth J Radford; Sui Yu; Jozef Gecz; Nicholas G Martin; Caroline F Wright; David R Fitzpatrick; Helen V Firth; Matthew E Hurles; Jeffrey C Barrett
Journal:  Nature       Date:  2018-09-26       Impact factor: 49.962

Review 9.  Insights into genetics, human biology and disease gleaned from family based genomic studies.

Authors:  Jennifer E Posey; Anne H O'Donnell-Luria; Jessica X Chong; Tamar Harel; Shalini N Jhangiani; Zeynep H Coban Akdemir; Steven Buyske; Davut Pehlivan; Claudia M B Carvalho; Samantha Baxter; Nara Sobreira; Pengfei Liu; Nan Wu; Jill A Rosenfeld; Sushant Kumar; Dimitri Avramopoulos; Janson J White; Kimberly F Doheny; P Dane Witmer; Corinne Boehm; V Reid Sutton; Donna M Muzny; Eric Boerwinkle; Murat Günel; Deborah A Nickerson; Shrikant Mane; Daniel G MacArthur; Richard A Gibbs; Ada Hamosh; Richard P Lifton; Tara C Matise; Heidi L Rehm; Mark Gerstein; Michael J Bamshad; David Valle; James R Lupski
Journal:  Genet Med       Date:  2019-01-18       Impact factor: 8.822

Review 10.  Inherited Platelet Disorders: An Updated Overview.

Authors:  Verónica Palma-Barqueros; Nuria Revilla; Ana Sánchez; Ana Zamora Cánovas; Agustín Rodriguez-Alén; Ana Marín-Quílez; José Ramón González-Porras; Vicente Vicente; María Luisa Lozano; José María Bastida; José Rivera
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.